Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Organon & Co. Common Stock
(NY:
OGN
)
7.710
-0.030 (-0.39%)
Official Closing Price
Updated: 5:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organon & Co. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
November 25, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
Organon & Co.
Via
Business Wire
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
From
Organon & Co.
Via
Business Wire
Earnings Scheduled For November 10, 2025
↗
November 10, 2025
Via
Benzinga
A Look at Organon's Upcoming Earnings Report
↗
November 07, 2025
Via
Benzinga
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call
November 17, 2025
Organon's third quarter was marked by better-than-expected top-line and bottom-line results, which were well received by the market. Management attributed the quarter’s outperformance to strong...
Via
StockStory
Topics
Earnings
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
November 14, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Organon (OGN) Stock Trades Down, Here Is Why
November 11, 2025
Shares of pharmaceutical company Organon (NYSE:OGN) fell 2.9% in the afternoon session after the company lowered its full-year sales guidance and analysts subsequently cut their price targets on the...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Supply Chain
Organon Analysts Cut Their Forecasts Following Q3 Results
↗
November 11, 2025
Via
Benzinga
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration
November 11, 2025
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s...
Via
StockStory
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?
↗
November 10, 2025
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...
Via
Benzinga
Organon Cuts 2025 Sales Outlook Despite Earnings Beat
↗
November 10, 2025
Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children with atopic dermatitis.
Via
Benzinga
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3
November 10, 2025
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s...
Via
StockStory
Organon Reports Results for the Third Quarter Ended September 30, 2025
November 10, 2025
From
Organon & Co.
Via
Business Wire
Organon (OGN) Reports Earnings Tomorrow: What To Expect
November 08, 2025
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
November 08, 2025
From
Organon & Co.
Via
Business Wire
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
November 07, 2025
From
Organon & Co.
Via
Business Wire
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
November 06, 2025
From
Organon & Co.
Via
Business Wire
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
November 02, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via
StockStory
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 We Ignore
October 29, 2025
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
Why Organon (OGN) Stock Is Down Today
October 28, 2025
Shares of pharmaceutical company Organon (NYSE:OGN) fell 8.9% in the afternoon session after the company announced the resignation of CEO Kevin Ali after an internal investigation uncovered improper...
Via
StockStory
Topics
Economy
Government
Initial Public Offering
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
October 28, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation
October 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation
October 27, 2025
Via
TheNewswire.com
Which stocks are moving on Monday?
↗
October 27, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Keep an eye on the top gainers and losers in Monday's session.
↗
October 27, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 27, 2025
Via
Benzinga
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings
↗
October 27, 2025
Via
Benzinga
Which stocks are gapping on Monday?
↗
October 27, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
These stocks are moving in today's pre-market session
↗
October 27, 2025
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today